HCPCS Level II code J1950 denotes an injectable depot formulation of leuprolide acetate, billed per 3.75 mg. As a GnRH agonist, leuprolide acetate is used to suppress gonadal hormone production for conditions such as prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. This code captures the drug component for administration in outpatient settings and is significant for specialty drug billing and oncology, urology, and gynecology practice revenue cycles.

Key national payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer-specific coverage nuances, typical site-of-service settings, and commonly reported modifiers but does not provide state-level policy detail.

Readers will find: a concise description of what J1950 represents clinically and operationally; standard billing contexts for depot injections; benchmark reimbursement and utilization considerations; and guidance on documentation and claim submission elements relevant to injectable specialty pharmaceuticals. Data gaps are noted where input information is incomplete. The emphasis is on national policy and billing context rather than clinical treatment recommendations.